The Prof. Amedeo Amedei is affiliate of the Department of Experimental and Clinical Medicine (University of Florence) and member in the Scientific Council of Departments of Excellence (Medicine of migrants). Amedeo Amedei was born on 01.04.1971. On 1996 July, he graduated with full marks and honours in Biology at Florence University. He has started his scientific career with a scholarship (1997-1999) studying the role of Th1/Th2 lymphocytes in several diseases (graft versus host disease, atopic dermatitis, kidney rejection crisis). From 2000 to 2002, he has examined the cellular and molecular mechanisms that regulate the gastric chronic inflammatory process; particularly he studied the role of specific immune response versus Helicobacter pylori in gastric diseases (gastritis-ulcer, Malt-lymphoma, gastric cancer, autoimmune gastritis). On January 2003 began his doctor’s degree in "Clinical and Sperimental Medicine". From February to December 2003 he has collaborated on the " Stem cells and immune-therapy of cancer” financed project of Tuscany Region. In March 2005, he became a scientific researcher at Department of Experimental and Clinical Medicine (University of Florence), where in November 2015 he was appointed Associate Professor. In 31/03/2017, the Prof. Amedei received the qualification as Full Professor. In the last years, the Prof. Amedei has focused his scientific interests on the cancer, studying, the anti-cancer immune response and the role of cancer microenvironment. In detail, the quality of immune response, exploring the role of the different T cells’ subset: effector (e.g Th1, Th17, Th9 ..) and regulatory (Tregs). For the important scientific impact of obtained data, he was a member of the team of researchers involved in the world project "Halifax Project" (http://www.gettingtoknowcancer.org/). The project involves about 300 international researchers, divided into two working groups (I = advanced cancer treatments and II = carcinogenic potential of exposure to low doses of mixtures of chemicals in the environment). The data have produced 11 papers for the important cancer journal “Carcinogenesis” and 12 articles for the prestigious scientific journal “Seminars in Cancer Biology”. The Prof. Amedei is co-author of all 23 manuscripts. The current scientific topic of Prof. Amedei is the evaluation of the correlation between the microbiome and the immune response in the genesis of inflammatory-correlated diseases. In detail colorectal cancer, celiac disease, Inflammatory Bowel Diseases, Becet Diseases and Amyotrophic Lateral Sclerosis (ALS). The great quality of his international profile is documented by scientific production that, to date, is composed of 138 peer reviewed articles (https://www.ncbi.nlm.nih.gov/pubmed/?term=amedei+a ), H-index: 52 and 8177 Citations (https://scholar.google.it/citations?user=alJDmrgAAAAJ&hl=it ), 8 book chapters and one patent (WO/2007/039451), in addition to active participation in various (57) national/international congress. In addition, the Prof. Amedei is Co-Editor in Chief or member of the Editorial Board of 20 International scientific journals and finally, he regularly carries out activities as scientific reviewer for international research projects of private and public entities: 2012 - Latvian Science Council (Latvia); 2013 - Latvian Science Council (Latvia); 2015 - Government agency of National Science Centre (Narodowe Centrum Nauki – NCN- Poland); 2015 - MS Research Australia (MSRA) (Australia); 2015- Université de Toulouse (France).; 2016 - FWF Austrian Science Fund (Austria); 2017 - Università degli Studi di Roma "Tor Vergata" (Italy), FWF Austrian Science Fund (Austria). 2018- European Science Foundation (Belgium), French National Cancer Institute (France), King Abdullah International Medical Research Center (KAIMRC) (Saudi Arabia). From 2016, he is in the Scientific Council of “Toscana Life Sciences” (TLS). Finally, as derived from the Scival data (https://www.elsevier.com/solutions/scival), Prof. Amedei is among the top 500 Italian researchers (exactly at 203 position) most influential in cancer research.